ImmunityBio Inc. Common Stock vs UBS Group AG Registered Ordinary Shares — how do they compare? ImmunityBio Inc. Common Stock trades at $10.28 (market cap $10.51B), while UBS Group AG Registered Ordinary Shares trades at $47.99 (market cap $142.70B). The key difference: UBS Group AG Registered Ordinary Shares is far larger — about 13.6× ImmunityBio Inc. Common Stock's market cap, and UBS Group AG Registered Ordinary Shares pays a 2.34% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and UBS Group AG Registered Ordinary Shares for 0 Days on average.
| IBRX | UBS | |
|---|---|---|
Market Cap | $10.51B | $142.70B |
Volume | 10,445,785 | 2,096,090 |
Sector | Health | Financials |
52-Week High | $11.55 | $55.72 |
52-Week Low | $1.98 | $36.41 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.97B | $314.41B |
Dividend Yield | — | 2.34% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.
Read more on UBS →